Cyto-Facto
Cyto-Facto is a Japan-based CDMO operating PIC/S GMP- and CGTP-compliant facilities in Kobe, providing end-to-end contract development, manufacturing, and quality testing services for cell and gene therapy products including CAR-T, MSC, and iPSC-derived modalities for global pharmaceutical and biotech clients.
- Company typePrivate
- Founded2022
- HeadquartersMinamimachi, Japan
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Cyto-Facto does
Cyto-Facto Inc. is a privately held contract development and manufacturing organization (CDMO) headquartered in Kobe, Japan, specializing in cell and gene therapy (CGT) products. The company operates PIC/S GMP- and CGTP-compliant facilities at the Kobe Medical Innovation Center, providing end-to-end services spanning process development, GMP manufacturing, and quality control testing for gene and cell preparations. Its core modalities include CAR-T cell therapies, mesenchymal stem cell (MSC) products, and iPSC-derived therapies, with supporting capabilities in viral vector production for gene therapies (including GMP-compliant lentiviral systems such as the VirusExpress 293T platform).
The company originated as the first commercial manufacturing site in Asia for Kymriah, the world's first approved CAR-T therapy, and has since manufactured and shipped hundreds of batches of CAR-T product under standards required by global pharmaceutical companies. Its proprietary technology stack includes a CAR-T manufacturing platform, a viral vector production platform with suspension-based scale-up in single-use bioreactors, and the VirusExpress 293T Lentiviral Production Cells system. The company employs 64 staff including 9 PhDs and 22 master's degree holders with experience spanning basic research through commercial manufacturing.
Cyto-Facto generates revenue through professional services contracts — contract manufacturing, contract development (process development, scale-up, automation, SOP creation), and quality control testing — under individually negotiated agreements with pharmaceutical and biotech clients. Its go-to-market is enterprise B2B sales targeting global pharma and gene/cell therapy developers, primarily in the Asia-Pacific region, with active expansion into Southeast Asia (Vietnam), South Asia (India via Merck referral), and Taiwan. Recent strategic partnerships with Merck KGaA, Thermo Fisher Scientific, Hoa Lam Shangri-La Healthcare, and Steminent Biotherapeutics, combined with selection for METI's Regenerative CDMO Subsidy program in 2025, indicate an ongoing transition from a single-product (Kymriah) manufacturing site toward a diversified, multi-modality CGT CDMO serving the broader Asia-Pacific market.
Cyto-Facto firmographics
Firmographics- Name
- Cyto-Facto
- Legal name
- 株式会社サイト・ファクト (Cyto-Facto Inc.)
- Website
- https://cytofacto.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cyto-Facto is a Japan-based CDMO operating PIC/S GMP- and CGTP-compliant facilities in Kobe, providing end-to-end contract development, manufacturing, and quality testing services for cell and gene therapy products including CAR-T, MSC, and iPSC-derived modalities for global pharmaceutical and biotech clients.
- Ownership category
- akta.pro rank
Cyto-Facto industry classification
Industry- Product category
- Biopharmaceutical CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Therapy CDMO (HLAGABAD)
Keywords
Where Cyto-Facto is headquartered
LocationHeadquarters
- HQ city
- Minamimachi
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
Cyto-Facto business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Manufacturing services for cell and gene therapy products including CAR-T, MSC, and iPSC-derived products under GMP and CGTP-compliant environments.
- Quality Control Testing Services: Quality control testing and characterization analysis services for gene and cell preparations.
- Contract Development Services: Process development services including scale-up, equipment selection, closed system construction, automation implementation, and manufacturing SOP creation.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Cyto-Facto product offering
Product offeringCore offering
Cyto-Facto is a Contract Development and Manufacturing Organization (CDMO) that provides end-to-end manufacturing, development, and quality control testing services for gene and cell therapy products, including CAR-T, mesenchymal stem cell (MSC), and iPSC-derived therapies, under PIC/S GMP- and CGTP-compliant conditions from its Kobe, Japan facilities. The company serves global pharmaceutical and biotech clients, covering the full lifecycle from early-stage process development through commercial-scale manufacturing, with a proven track record as the first commercial manufacturing site in Asia for Kymriah.
Product overview
Cyto-Facto is a Contract Development and Manufacturing Organization (CDMO) specializing in gene and cell therapies. The company operates as a single integrated service offering rather than a modular platform. Its core capabilities include manufacturing, development, and quality control testing of gene and cell preparations. The company supports multiple therapy modalities (CAR-T, MSC, and iPSC-derived products) and provides end-to-end services from early development through commercial manufacturing. Cyto-Facto operates PICS GMP- and CGTP-compliant facilities in Kobe, Japan, and has established itself as the first commercial manufacturing site in Asia for the world's first cell and gene therapy product, Kymriah (CAR-T cell therapy).
Differentiator
Problem solved
Functional benefit
Products and services
- Contract Development and Manufacturing Services End-to-end CDMO services covering manufacturing, development, and quality control testing of gene and cell preparations from early development through commercial manufacturing, sold to global pharmaceutical and biotech clients.
- CAR-T Cell Manufacturing Contract manufacturing of CAR-T cell products under PIC/S GMP management, with a proven track record of stably manufacturing and shipping hundreds of batches at the quality standards required by global pharmaceutical companies.
- MSC and iPSC-Derived Product CDMO Services Contract manufacturing services for mesenchymal stem cell (MSC) and iPSC-derived regenerative medicine products, including contract manufacturing of Stemchymal for Steminent Biotherapeutics.
- Viral Vector Production Services Process development and contract manufacturing of clinical-grade viral vectors, including suspension-based scale-up of viral vectors in single-use bioreactors and lentiviral production using the VirusExpress 293T Lentiviral Production Cell system under GMP conditions for gene therapy developers.
- Quality Control Testing Services Quality control testing and characterization analysis services for gene and cell preparations, supporting manufacturing release and regulatory compliance for cell and gene therapy products.
Quantifiable outcome
- Hundreds of batches of CAR-T cell products stably manufactured and shipped
- +1 more outcomes
Companies that use Cyto-Facto
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Cyto-Facto technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cyto-Facto partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Merck KGaAcoreMerck signed MoU with Cyto-Facto to combine Merck's technology platforms with Cyto-Facto's manufacturing capabilities for gene therapy development and manufacturing in Asia-Pacific. Partnership includes support for lentiviral production using VirusExpress 293T Lentiviral Production Cells in GMP-compliant environments. Merck India will facilitate knowledge exchange and connect Cyto-Facto with Indian CGT companies seeking specialized CDMO services.
- Steminent Biotherapeutics Inc.coreLetter of Intent signed for contract manufacturing of Steminent's Mesenchymal stem cell product Stemchymal. Partnership involves detailed discussions toward establishing manufacturing framework, facility preparations, and future technology transfer for commercial production.
- Hoa Lam Shangri-La Healthcare (Vietnam)coreMoU signed to promote technical education and business development in cell, stem cell, and gene therapy. Cyto-Facto will provide training, consulting, and technology transfer for manufacturing cells and stem cells according to Japanese quality standards, contributing to building a Southeast Asian network for gene and cell therapy.
- Thermo Fisher Scientific JapancoreMoU signed for process development cooperation on manufacturing of viral vectors for clinical applications. Partnership aims to develop processes for suspension-based scale up of viral vectors in single-use bioreactors at Kobe Medical Innovation Center to expedite clinical-grade viral vector provision.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Cyto-Facto competitors and assessment
Company assessmentOthers
Emerging players
- Cellares: Emerging cell therapy manufacturing technology company developing automated, closed-system Cell Shuttles for autologous cell therapy production. Comparable as a next-generation cell therapy manufacturing platform targeting the same CDMO market.
Broad incumbents
- Lonza Cell & Gene Technologies: World's largest CDMO with a dedicated Cell & Gene Technologies business offering autologous and allogeneic cell therapy manufacturing, viral vector production, and process development. Competes with Cyto-Facto for global pharma CGT outsourcing.
- Catalent Cell Therapy: Major CDMO with cell therapy manufacturing facilities in the U.S. and Europe offering commercial-scale CAR-T production. Comparable as a commercial-stage cell therapy CDMO targeting similar global pharma sponsors.
- WuXi Advanced Therapies (WuXi AppTec): Large Asia-headquartered CDMO with cell and gene therapy manufacturing capabilities. Direct overlap with Cyto-Facto's Asia-Pacific CGT CDMO positioning, with significantly larger scale and capital base.
Direct peers
- Yposkesi: France-based cell and gene therapy CDMO offering viral vector and cell therapy manufacturing services. Comparable as a focused CGT CDMO serving similar biotech and pharma clients globally.
- AGC Biologics: Global CDMO with mammalian and cell therapy manufacturing capabilities including a strong presence in Japan (Yokohama). Comparable as a cell therapy and biologics CDMO serving similar biotech and pharma customers.
- Minaris Regenerative Medicine: Japan-based cell therapy CDMO (formerly Hitachi Chemical) offering commercial and clinical manufacturing for regenerative medicine and cell therapies. Directly comparable to Cyto-Facto in modality, geography, and Japan-based operations.
- Takara Bio: Japan-based biotechnology company providing cell therapy products, viral vector manufacturing, and regenerative medicine services. Comparable as a Japan-based cell and gene therapy products and services provider.
- Nikon CeLL innovation: Japan-based cell therapy CDMO subsidiary of Nikon, offering contract manufacturing for regenerative medicine products. Closest geographic and modality peer to Cyto-Facto within Japan.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Cyto-Facto compliance and trust
Trust signalCompliance2 records
Cyto-Facto financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cyto-Facto leadership team
Management profileNumber of profiles
Profiles1 record
Cyto-Facto funding detail
Funding detailFunding overview
Funding rounds1 record
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cyto-Facto M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cyto-Facto
What does Cyto-Facto do?
Cyto-Facto is a Contract Development and Manufacturing Organization (CDMO) that provides end-to-end manufacturing, development, and quality control testing services for gene and cell therapy products, including CAR-T, mesenchymal stem cell (MSC), and iPSC-derived therapies, under PIC/S GMP- and CGTP-compliant conditions from its Kobe, Japan facilities. The company serves global pharmaceutical and biotech clients, covering the full lifecycle from early-stage process development through commercial-scale manufacturing, with a proven track record as the first commercial manufacturing site in Asia for Kymriah.
Is Cyto-Facto a public or private company?
Cyto-Facto is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cyto-Facto founded?
Cyto-Facto was founded in 2022. It employs 51 to 100 people.
Where is Cyto-Facto based?
Cyto-Facto is headquartered in Minamimachi, Japan, in the Asia region.
How does Cyto-Facto make money?
Three revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are quality Control Testing Services and contract Development Services.
Who are Cyto-Facto's main competitors?
Charles River Laboratories is listed as an others. Cellares is listed as an emerging player. Broad incumbents are Lonza Cell & Gene Technologies, Catalent Cell Therapy and WuXi Advanced Therapies (WuXi AppTec). Direct peers are Yposkesi, AGC Biologics, Minaris Regenerative Medicine, Takara Bio and Nikon CeLL innovation.
Does Cyto-Facto have an API?
No public API is recorded for Cyto-Facto.
What industry is Cyto-Facto in?
Cyto-Facto's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO. Its NAICS code is 325414 and its SIC code is 2834.